Artios is a clinical-stage biopharmaceutical company focused on developing cancer therapies that target the DNA Damage Response pathway. Based at the Babraham Campus in Cambridge, UK, it has built a pipeline of DDR inhibitors including alnodesertib (ATR inhibitor) and a Pol Theta inhibitor program. Co-founded in 2016 by pioneering DDR researchers, Artios raised $115M in a Series D in 2025.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account